Meeting Coverage. Tocilizumab responses durable to 2 years in juvenile idiopathic arthritis.
- Published in:
- 2012
- Publication type:
- Journal Article
Works matching IS 1082801X AND DT 2012 AND VI 47 AND IP 2
Results: 23
1
2
Drug Watch. Cardiovascular agents.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 84
- Publication type:
- Article
3
Policy Watch. Health reform promises expanded drug coverage through ACOs, exchanges, value-based initiatives.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 82
- By:
- Publication type:
- Article
4
Meeting Coverage. More than one-fourth of rheumatoid arthritis patients respond to methotrexate-first strategy.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 81
- Publication type:
- Article
5
Medication Safety and Reliability. FDA warns of Durezol/Durasal name confusion.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 80
- Publication type:
- Article
6
Medication Safety and Reliability. FDA notes conflicting results of SSRI use during pregnancy and risk of PPHN.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 80
- Publication type:
- Article
7
Medication Safety and Reliability. FDA adverse drug events app for public health crises could expand to more general adverse event reporting.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 79
- By:
- Publication type:
- Article
8
Most would reserve rivaroxaban as second-line therapy for patients with chronic atrial fibrillation.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 78
- Publication type:
- Article
9
Immunization update: A 2011 retrospective on product changes and new recommendations.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 58
- By:
- Publication type:
- Article
10
Orally inhaled dihydroergotamine: A novel ergot delivery method for the treatment of migraine.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 54
- By:
- Publication type:
- Article
11
FDA reports increased risk of death in patients with permanent AF taking dronedarone, revises drug label.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 48
- Publication type:
- Article
12
AAN and ILAE release guidelines for the use of antiepileptic drugs in patients with HIV/AIDS.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 50
- Publication type:
- Article
13
Treatment response to antidepressants similar in MDD patients with and without medical comorbidities.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 49
- Publication type:
- Article
14
Rivaroxaban reduces combined risk of cardiovascular death, myocardial infarction, or stroke in ACS patients.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 49
- Publication type:
- Article
15
FDA modifies REMS for 2 platelet-booster drugs: Enrollment in safety programs no longer required for prescribers, dispensers.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 48
- Publication type:
- Article
16
Romiplostim induces rapid platelet response in adult patients with immune thrombocytopenia.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 53
- Publication type:
- Article
17
FDA advisory panel recommends stronger warning for drospirenone-containing birth control.
- Published in:
- 2012
- Publication type:
- Proceeding
18
Hospital-acquired C. difficile lengthens hospital stay, retrospective study shows.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 47
- Publication type:
- Article
19
FDA Drug Approvals. First-time generic approvals.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 46
- Publication type:
- Article
20
FDA Drug Approvals. FDA actions in brief.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 46
- Publication type:
- Article
21
FDA Drug Approvals. New indication.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 45
- Publication type:
- Article
22
FDA Drug Approvals. New molecular entity.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 45
- Publication type:
- Article
23
FDA Drug Approvals. Pipeline review.
- Published in:
- Formulary, 2012, v. 47, n. 2, p. 45
- Publication type:
- Article